Terms: = Leukemia AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Treatment
1648 results:
1. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR and ddPCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM
Methods Mol Biol; 2025; 2865():189-219. PubMed ID: 39424725
[TBL] [Abstract] [Full Text] [Related]
2. Synthesis, Anti-Cancer Activity, Cell Cycle Arrest, Apoptosis Induction, and Docking Study of Fused Benzo[
Khoder ZM; Mohamed MS; Awad SM; Gharib AF; Aly O; Khodair MAE; Fatahala SS; El-Hameed RHA
Molecules; 2024 Oct; 29(19):. PubMed ID: 39407625
[TBL] [Abstract] [Full Text] [Related]
3. [Report of six cases with mast cell leukemia and a literature review].
Zhu F; Yu Y; Chen CY; Duan WB; Jiang Q; Yan R; Sun Y; Han YQ; Zhang J; Wang H; Zhang QR; Chen SN; Yan WH; Cai MJ; Zhang ZB; Yin J; Wang Q
Zhonghua Nei Ke Za Zhi; 2024 Oct; 63(10):996-1000. PubMed ID: 39375119
[TBL] [Abstract] [Full Text] [Related]
4. SRPK Inhibitors Reduce the Phosphorylation and Translocation of SR Protein Splicing Factors, thereby Correcting
Changphasuk P; Inpad C; Horpaopan S; Khunchai S; Phimsen S; Surangkul D; Janvilisri T; Silsirivanit A; Kaewkong W
Front Biosci (Schol Ed); 2024 Sep; 16(3):17. PubMed ID: 39344395
[TBL] [Abstract] [Full Text] [Related]
5. NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia.
Lu Y; Jiang X; Li Y; Li F; Zhao M; Lin Y; Jin L; Zhuang H; Li S; Ye P; Pei R; Jin J; Jiang L
J Transl Med; 2024 Sep; 22(1):867. PubMed ID: 39334157
[TBL] [Abstract] [Full Text] [Related]
6. CRISPR screen of venetoclax response-associated genes identifies transcription factor ZNF740 as a key functional regulator.
Zhang L; Zhou X; Aryal S; Veasey V; Zhang P; Li FJ; Luan Y; Bhatia R; Zhou Y; Lu R
Cell Death Dis; 2024 Aug; 15(8):627. PubMed ID: 39191721
[TBL] [Abstract] [Full Text] [Related]
7. Clitocine enhances the drug sensitivity of colon cancer cells by promoting FBXW7-mediated mcl-1 degradation via inhibiting the A2B/cAMP/ERK axis.
Ruan F; Ruan Y; Gu H; Sun J; Chen Q
Am J Physiol Cell Physiol; 2024 Oct; 327(4):C884-C900. PubMed ID: 39140602
[TBL] [Abstract] [Full Text] [Related]
8. Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States.
Peloquin S; Cymbalista F; Dreyling M; Shah NN; Murray S; Del Fiacco R; Muehlenbein CE; Lazure P
BMC Cancer; 2024 Aug; 24(1):1003. PubMed ID: 39138575
[TBL] [Abstract] [Full Text] [Related]
9. Altered neutrophil responses to dengue virus serotype three: delayed apoptosis is regulated by stabilisation of mcl-1.
Kamsom C; Edwards SW; Thaosing J; Papalee S; Pientong C; Kurosu T; Phanthanawiboon S
Sci Rep; 2024 Aug; 14(1):18414. PubMed ID: 39117747
[TBL] [Abstract] [Full Text] [Related]
10. Proteasome inhibition induces apoptosis through simultaneous inactivation of mcl-1/BCL-XL by NOXA independent of CHOP and JNK pathways.
Chen W; Sun M; Sun Y; Yang Q; Gao H; Li L; Fu R; Dong N
Toxicology; 2024 Nov; 508():153906. PubMed ID: 39117261
[TBL] [Abstract] [Full Text] [Related]
11. Discovery of a Myeloid Cell leukemia 1 (mcl-1) Inhibitor That Demonstrates Potent
Tarr JC; Salovich JM; Aichinger M; Jeon K; Veerasamy N; Sensintaffar JL; Arnhof H; Samwer M; Christov PP; Kim K; Wunberg T; Schweifer N; Trapani F; Arnold A; Martin F; Zhao B; Miriyala N; Sgubin D; Fogarty S; Moore WJ; Stott GM; Olejniczak ET; Engelhardt H; Rudolph D; Lee T; McConnell DB; Fesik SW
J Med Chem; 2024 Aug; 67(16):14370-14393. PubMed ID: 39102508
[TBL] [Abstract] [Full Text] [Related]
12. Initial AXL and mcl-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.
Matsui Y; Yamada T; Katayama Y; Hirai S; Sawada R; Tachibana Y; Ishida M; Kawachi H; Nakamura R; Nishioka N; Morimoto K; Iwasaku M; Horinaka M; Sakai T; Tokuda S; Takayama K
Cancer Sci; 2024 Oct; 115(10):3333-3345. PubMed ID: 39039802
[TBL] [Abstract] [Full Text] [Related]
13. A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS).
Choquet S; Marchal C; Deygas F; Deslandes M; Macher N; de Pouvourville G; Levy V
Ann Hematol; 2024 Aug; 103(8):2969-2981. PubMed ID: 38965145
[TBL] [Abstract] [Full Text] [Related]
14. Marine Cytotoxin Santacruzamate A Derivatives as Potent HDAC1-3 Inhibitors and Their Synergistic Anti-leukemia Effects with Venetoclax.
Hao W; Wang L; Xu T; Jia G; Jiang Y; Qin C; Li X
Mar Drugs; 2024 May; 22(6):. PubMed ID: 38921561
[TBL] [Abstract] [Full Text] [Related]
15. Extracellular vesicles from type-2 macrophages increase the survival of chronic lymphocytic leukemia cells ex vivo.
Ikhlef L; Ratti N; Durand S; Formento R; Daverat H; Boutaud M; Guillou C; Dmytruk N; Gachard N; Cosette P; Jauberteau MO; Gallet PF
Cancer Gene Ther; 2024 Aug; 31(8):1164-1176. PubMed ID: 38918490
[TBL] [Abstract] [Full Text] [Related]
16. Desmethylclomipramine triggers mitochondrial damage and death in TGF-β-induced mesenchymal type of A549 cells.
Shih FC; Lin CF; Wu YC; Hsu CC; Chen BC; Chang YC; Lin YS; Satria RD; Lin PY; Chen CL
Life Sci; 2024 Aug; 351():122817. PubMed ID: 38871113
[TBL] [Abstract] [Full Text] [Related]
17. Combining Mefloquine with an mcl-1 Inhibitor as a Novel Therapeutic Strategy for the treatment of Nasopharyngeal Carcinoma.
Dong J; Zhang J; Xiang G; Yang L
Nutr Cancer; 2024; 76(8):736-744. PubMed ID: 38795070
[TBL] [Abstract] [Full Text] [Related]
18. Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.
Wang M; Robak T; Maddocks KJ; Phillips T; Smith SD; Gallinson D; Calvo R; Wun CC; Munugalavadla V; Jurczak W
Blood Adv; 2024 Sep; 8(17):4539-4548. PubMed ID: 38781315
[TBL] [Abstract] [Full Text] [Related]
19. Patient perspectives on treatment for mantle cell lymphoma and chronic lymphocytic leukemia in Japan.
Kiguchi T; Hiramatsu Y; Ota S; Uchiyama M; Matsuo M; Okamura M; Morimoto S; Tanizawa Y; Tajimi M; Payakachat N
J Clin Exp Hematop; 2024 Jun; 64(2):119-128. PubMed ID: 38749721
[TBL] [Abstract] [Full Text] [Related]
20. TurboID-Based IRE1 Interactome Reveals Participants of the Endoplasmic Reticulum-Associated Protein Degradation Machinery in the Human Mast Cell leukemia Cell Line HMC-1.2.
Ahmed N; Preisinger C; Wilhelm T; Huber M
Cells; 2024 Apr; 13(9):. PubMed ID: 38727283
[TBL] [Abstract] [Full Text] [Related]
[Next]